{"title":"Oxford–AstraZeneca COVID-19 vaccine","summary":"The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222,[5] and sold under the brand names Covishield[22] and Vaxzevria[1][23] among others, is a viral vector vaccine for prevention of COVID-19. Developed in the United Kingdom by the Oxford University and British-Swedish company AstraZeneca,[24][25][26] using as a vector the modified chimpanzee adenovirus ChAdOx1.[27] The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose, and 81.3% after the second dose.[28] A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant (lineage B.1.1.7), and 61% against the Delta variant (lineage B.1.617.2).[29]","image":"Oxford_AstraZeneca_COVID-19_vaccine_AZD1222_-_4.jpg.webp"}